Clinical Trials Logo
  1. Home
  2. Inclusion Body Myositis
  3. NCT00898989
  4. Details
NCT00898989 Clinical Trial

Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis

Inclusion Body Myositis Clinical Trial

— IBMan  

Official title:
Evaluation of Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00898989
Other study ID # 2009-a00055-52
Secondary ID
Status Completed
Phase N/A
First received May 11, 2009
Last updated December 18, 2010
Start date April 2009
Est. completion date April 2010

Study information
Verified date December 2010
Source Institut de Myologie, France
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Observational

Clinical Trial Summary

Comparison of a group of 20 IBM patients with 20 controls matched on age, gender and weight.

Recruitment information / eligibility
Status Completed
Enrollment 42
Est. completion date April 2010
Est. primary completion date April 2010
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age > 18 years old

- Written consent

Exclusion Criteria:

- Current infection

- Cancer within 1 year

- Immune deficiency

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
France Hopital Pitié-Salpêtrière Paris

Sponsors (2)
Lead Sponsor Collaborator
Institut de Myologie, France Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary muscle strength 2 evaluations at an interval of 9 months No
Secondary immune response 1 measure at inclusion No
See also
  Status Clinical Trial Phase
Completed NCT00769860 - Arimoclomol in Sporadic Inclusion Body Myositis Phase 2/Phase 3
Completed NCT01165008 - Anakinra in Myositis Phase 2/Phase 3
Recruiting NCT05890833 - The Risk of Falls Index for Patients With Neuromuscular Disorders
Active, not recruiting NCT05046821 - Sporadic Inclusion Body Myositis Natural History Study
Recruiting NCT06153108 - Monitoring Biomarker for Detecting Change in Physical Activity and Limb Function in Inclusion Body Myositis Over Time
Active, not recruiting NCT04659031 - A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) Phase 1
Completed NCT03440034 - Study of Pioglitazone in Sporadic Inclusion Body Myositis Phase 1
Terminated NCT04049097 - Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial Phase 3
Completed NCT00001261 - Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies Phase 2
Recruiting NCT05272969 - Pompe & Pain - Study to Assess Nociceptive Pain in Adult Patients With Pompe Disease
Completed NCT01734369 - Environmental Risk Factors for Myositis in Military Personnel
Active, not recruiting NCT04975841 - Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells N/A
Recruiting NCT00017914 - Adult and Juvenile Myositis
Completed NCT00917956 - Lithium in Inclusion Body Myositis (IBM) N/A
Completed NCT03633318 - Establishing Muscle Impedance Parameters With Electrical Impedance Myography
Recruiting NCT04789070 - Phase III Trial of Sirolimus in IBM Phase 3
Active, not recruiting NCT05721573 - A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis Phase 2/Phase 3
Recruiting NCT05032131 - Cell Therapy for IBM by Muscle Injection of ADSVF Phase 1
Completed NCT03299335 - Molecular Profile of the Evolution of Inclusion Body Myositis N/A
Completed NCT04421677 - Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis Phase 1